2021年

December 27, 2021: Kyorin Signed Memorandum of Understanding on Co-Promotion of "Lagevrio Capsule 200mg" for COVID-19 Treatment
November 30, 2021: Launch of "Compact Real Time PCR System GeneSoC® mini"
November 8, 2021: Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2021) [Japanese Standard]
November 8, 2021: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
August 3, 2021: Summary of Consolidated Financial Results (August 3,2021) [Japanese Standard]
August 3, 2021: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
May 11, 2021: Summary of Consolidated Financial Results　(For the fiscal year ended March 31, 2021) [Japanese Standard]
May 11, 2021: Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 - Supplementary information
May 7, 2021: The Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2021
April 26, 2021: MSD and KYORIN Conclude Distribution Agreement of Gefapixant Citrate, a Treatment for Chronic Cough, in Japan
April 21, 2021: Launch of the Interstitial cystitis "Zymso® Intravesical Solution 50%"
March 31, 2021: KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
February 18, 2021: NHI Drug Price Listing and Release of injectable New Quinolone Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
February 4, 2021: Summary of Consolidated Financial Results (For the Second Quarter Ended December 31, 2020) [Japanese Standard]
February 4, 2021: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
January 29, 2021: Release of four research reagents for Microfluidic Real-Time PCR System GeneSoC®
January 22, 2021: Kyorin Pharmaceutical Receives Marketing Approval for the Interstitial cystitis "Zymso® Intravesical Solution 50%"